Moving from the present to the future of Postural Tachycardia Syndrome – What we need
Open accessAbstract
Our understanding about Postural Tachycardia Syndrome (POTS) has advanced significantly over the last 25 years. Despite the significant advances that have been made in defining the syndrome and finding some treatments for our patients, there is much work to be done to significantly improve our understanding of the disorder and improve therapeutics. In this article, 5 NEEDS are identified that will be required over the next several years if we want future care to move beyond where we are in the present. These include: (1) a NEED for better administrative data to track POTS diagnoses and the impact of the illness; (2) a NEED to improve physician awareness about POTS, which is a prerequisite for improved access to care; (3) a NEED to better understand the multiple pathophysiologies underlying POTS and the roles of the different medical comorbidities; (4) a NEED for data on effective treatments for POTS; and (5) a NEED for more research funding to study POTS.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
POTS is one of the most common disorders of the autonomic nervous system, with an estimated prevalence of 0.1%-1%.
“Postural orthostatic tachycardia syndrome is one of the most common disorders of the autonomic nervous system, with an estimated prevalence of 0.1%–1%.1,12,13”
From Diagnosis and management of postural orthostatic tachycardia syndrome (2022) · cites this paper as [13]
The section “Need Better Data on the Number of POTS Patients and the Impact of POTS” (page unavailable) estimates 300,000–3,000,000 US patients, a range broadly consistent with the quoted percentage, but calls it a “best guess” rather than a measured prevalence. The paper does not state that POTS is one of the most common autonomic disorders or give the 0.1%–1% figure explicitly. (LLM, conf=0.83)
Experimental — accuracy not yet measuredThe exact prevalence of POTS has not been determined.
“Postural orthostatic tachycardia syndrome (POTS) is common but the exact prevalence has not been determined”
From Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting - Part 1 (2021) · cites this paper as Raj and Robertson, 2018
The cause of POTS remains unclear.
“and the cause of this condition remains unclear.”
From Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting - Part 1 (2021) · cites this paper as Raj and Robertson, 2018
The epidemiology and natural history of POTS are not known.
“the epidemiology of the disorder and natural history are not known (Raj and Robertson, 2018).”
From Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting - Part 1 (2021) · cites this paper as Raj and Robertson, 2018
The three pathophysiologic mechanisms engender somewhat distinct variants of the POTS phenotype, referred to as endophenotypes.
“These three pathophysiologic mechanisms engender somewhat distinct variants of the POTS phenotype that henceforward will be referred to as endophenotypes (4).”
From Postural orthostatic tachycardia syndrome: mechanisms and new therapies (2020) · cites this paper as [4]
The literature has identified three different pathophysiologic mechanisms capable of manifesting the POTS phenotype: partial autonomic neuropathy, persistent predilection for hypovolemia, and central hyperadrenergic state.
“Thus far, the literature has identified three different pathophysiologic mechanisms that are capable of manifesting the POTS phenotype: ( a ) partial autonomic neuropathy, ( b ) persistent predilection for hypovolemia, and ( c ) central hyperadrenergic state.”
From Postural orthostatic tachycardia syndrome: mechanisms and new therapies (2020) · cites this paper as [4]
POTS patients will sometimes manifest features from more than one of the three major POTS endophenotypes.
“POTS patients will sometimes manifest features from more than one of the three major POTS endophenotypes (4).”
From Postural orthostatic tachycardia syndrome: mechanisms and new therapies (2020) · cites this paper as [4]
Improving clinician awareness can help improve the shortcomings in POTS diagnosis.
“Improving clinician awareness can help improve all of these shortcomings (4).”
From Postural orthostatic tachycardia syndrome: mechanisms and new therapies (2020) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 17 · Cited by 22
- Authors
- Raj, S. R., & Robertson, D.
- Affiliations
- University of Calgary (CA)
- Vanderbilt University Medical Center (US)
- Corresponding author
- Raj, Satish R.
- ORCID
- Raj, Satish R.
- Venue
- Autonomic Neuroscience
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 215
- Pages
- 126-128
- ISSN
- 1566-0702 (ISSN-L)
- PMC
- PMC6293980
- OpenAlex
- W2811322829
- Cited by
- 22
- References
- 17
- Citations by year
- 2026: 2 · 2024: 2 · 2023: 1 · 2022: 6 · 2021: 5 · 2020: 4 · 2019: 2
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Autonomic Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Allergan
- National Institutes of Health (UL1 TR000445)
- Boston Scientific Corporation
- Abbott Laboratories
- Canadian Institutes of Health Research (MOP142426)
- National Center for Advancing Translational Sciences
- Vanderbilt Institute for Clinical and Translational Research
- GE Healthcare
- Topics
- Health Sciences › Medicine › Surgery › Cardiovascular Syncope and Autonomic Disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Health Sciences › Medicine › Neurology › Long-Term Effects of COVID-19
- Keywords
- postural orthostatic tachycardia syndrome, administrative data, physician awareness, health care access, pathophysiology, comorbidities, research funding, future research priorities
- MeSH terms
- Humans, History, 20th Century, History, 21st Century, Postural Orthostatic Tachycardia Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
